Business Context and Reporting Period
This Form 8-K is filed by ReShape Lifesciences Inc. (trading symbol: RSLS) on June 18, 2025. The report addresses a critical listing status event regarding the company's compliance with The Nasdaq Capital Market requirements.
Key Financial Metrics and Liquidity
- Stockholders' Equity (as of March 31, 2025): $1.2 million (below the $2.5 million Nasdaq minimum).
- Stockholders' Equity (as of June 18, 2025): Greater than $2.5 million (restored compliance).
- Recent Capital Raises:
- June 3–6, 2025: Sold 593,000 shares for gross proceeds of $3,642,564 via an at-the-market offering.
- June 9, 2025: Sold 1,054,604 shares for gross proceeds of $2,636,510.
- Total Recent Proceeds: Approximately $6.28 million from the two equity offerings.
Material Changes
The primary material change is the restoration of stockholders' equity to meet Nasdaq Listing Rule 5550(b)(1). The company previously received a delisting notice on May 28, 2025, due to equity falling below the $2.5 million threshold. The recent equity offerings have increased equity above this requirement.
Outlook, Risks, and Management Commentary
- Delisting Risk: Management notes that current compliance does not guarantee the securities will not be delisted.
- Regulatory Action: The company has timely requested a hearing before a Nasdaq Hearings Panel. This request stays any suspension or delisting action pending the Panel's decision and any granted extensions.
- Unusual Items: The filing is driven by a regulatory compliance event rather than operational performance.
Investor Verification Checklist
- Verify the final decision of the Nasdaq Hearings Panel regarding the delisting notice.
- Confirm the exact post-offering stockholders' equity figure in the next quarterly report (10-Q).
- Review the terms of the equity distribution agreement with Maxim Group LLC for ongoing dilution risks.
- Monitor future cash burn rates to ensure equity remains above the $2.5 million threshold.